Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
Meta-analysis reveals key risk factors for liver toxicity in cancer patients receiving immunotherapy
Meta-analysis shows ICI rechallenge may be safe and effective for some cancer patients who stopped treatment
Meta-analysis investigates sex-based differences in adverse events for cancer patients on immunotherapy
Phase 3 trial shows no benefit of adding immune checkpoint inhibitor to targeted therapy in RCC patients